Human Respiratory Epithelial Tissue Models for Opioid-Reversal Nasal Spray Perme
Forecast New Requirement Updated
- Agency
-
Food and Drug Administration
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $25,000 to $250,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- Not on record
- Points of contact
-
- CDER Acquisition Liaison cderacquisitions@fda.hhs.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The Food and Drug Administration is procuring specialized human-derived nasal and respiratory epithelial tissue models and associated culture media for FDA-funded opioid-overdose reversal research, with solicitation release targeted for November 1, 2026, and award anticipated January 1, 2027. The tissues will support in vitro permeation testing of naloxone and nalmefene nasal spray formulations across physiologically relevant epithelial barriers to generate biorelevant data for generic drug development and evaluate alternative in vitro approaches for non-Q1/Q2 opioid-overdose reversal products.
The estimated award value ranges from $25,000 to $250,000. The purchase involves batch orders of 3D human-derived respiratory epithelial tissue models for permeation studies as identified in the funded research proposal. Questions and inquiries should be directed to the FDA Acquisition Liaison at cderacquisitions@fda.hhs.gov.
Forecast text
This contract will provide specialized human-derived nasal and respiratory epithelial tissue models and associated culture media required for the FDA-funded project "In Vitro Characterization to Support Development and Approval of Generic Drug Products for Opioid Overdose Reversal" under opioids research awards. The tissues will be used to test permeation of naloxone and nalmefene nasal spray products across physiologically relevant epithelial barriers, generating biorelevant in vitro data to evaluate formulation-dependent drug absorption and support development of alternative in vitro approaches for non-Q1/Q2 generic opioid-overdose reversal products. The purchase is specifically anticipated in the awarded proposal, which allocates project funds for batch orders of 3D human-derived respiratory epithelial tissue models needed for the permeation studies.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast